Managing IP is part of the Delinian Group, Delinian Limited, 8 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 00954730
Copyright © Delinian Limited and its affiliated companies 2023

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

SPCs demystified in our next webinar

Our next webinar on June 23 will discuss the latest developments regarding supplementary protection certificates (SPCs) in Europe

Drugs

The SPC regime, which dates back to 1992, has the relatively straightforward and uncontroversial purpose of extending protection for pharmaceutical (and some other) products whose launch is delayed by the regulatory process.

However, its application in practice has been complex, with many cases generating questions over the definition, scope and term of SPCs, as well as their application in different EU member states.

Continuing uncertainty

Because the regime is based on an EU Regulation, national courts have had to refer many of these questions to the Court of Justice of the EU in the hope of getting a clear ruling. Unfortunately, that hope has not always been fulfilled, leading to continuing uncertainty for many in the industry.

EU flag

Our webinar on June 23, which starts at 5pm London time, will feature Mike Gilbert and Angus Fairbairn of specialist IP firm Marks & Clerk and Dr Jocelyn Man of Gilead Sciences, and I will be moderating it.

The speakers will briefly set out the background to the SPC regime, before discussing the latest decisions from the CJEU and other open issues. These include questions such as: what does “protected by a basic patent” mean? And what is “active ingredient”? Jocelyn will also be able to provide a perspective from industry on the value of SPCs and the kinds of issues that pharma companies face.

In an industry where sales of blockbuster products can be counted in the millions of dollars per day, understanding the latest law on SPCs is vital for both originator and generic companies, so I’m sure this webinar will be of interest to all those in the industry around the world, as well as those who advise them in Europe and elsewhere.

Like all our webinars, you can easily view and listen from your desk (or anywhere with an internet connection) and there will be opportunities to ask questions of the speakers too. The webinar will last about one hour and if you can’t make next Tuesday, you can listen again at any convenient time. Registration is free, but must be done in advance.

more from across site and ros bottom lb

More from across our site

Counsel are eying domestic industry, concurrent PTAB proceedings and heightened scrutiny of cases before institution
Jack Daniel’s has a good chance of winning its dispute over dog toys, but SCOTUS will still want to protect free speech, predict sources
AI users and lawyers discuss why the rulebook for registering AI-generated content may create problems and needs further work
We provide a rundown of Managing IP’s news and analysis coverage from the week, and review what’s been happening elsewhere in IP
A technical effect must still be evident in the original patent filing, the EBoA said in its G2/21 decision today, March 23
Brands should not be deterred from pursuing lookalike producers, and an unfair advantage claim could be the key, say Emma Teichmann and Geoff Steward at Stobbs
Justice Mellor’s highly anticipated ruling surprised SEP owners and reassured implementers that the UK may not be so hostile after all
The England and Wales High Court's judgment comes ahead of a separate hearing concerning one of the patents-in-suit at the EPO
While the rules allow foreign firms to open local offices and offer IP services, a ban on litigation and practising Indian law could mean little will change
A New York federal court heard oral arguments this week in a copyright case pitting publishing giants against a digital library